The safety and efficacy of maintenance olaparib (Lynparza) in patients with BRCA1/2-mutated metastatic pancreatic cancer proved to be consistent irrespective of age, according to results of a subgroup analysis from the pivotal phase 3 POLO trial presented during the 2020 ESMO World Congress on Gastrointestinal Cancer.
Results showed that patients within the study who were at least 65 years old and received olaparib as a maintenance therapy were able to obtain long-term progression-free survival (PFS) and a durable tumor response. Read more . . .